Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
73 hedge funds and large institutions have $96.8M invested in Merrimack Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 55 closing their positions.
888% more call options, than puts
Call options by funds: $553K | Put options by funds: $56K
23% more capital invested
Capital invested by funds: $78.7M → $96.8M (+$18.1M)
12% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 25
39% less funds holding
Funds holding: 119 → 73 (-46)
80% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 55
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$5.21M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$4.51M |
| 3 |
WIM
Wittenberg Investment Management
Carlisle,
Massachusetts
|
+$869K |
| 4 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
+$573K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$435K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.91M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$1.65M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$930K |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$708K |
| 5 |
Morgan Stanley
New York
|
-$455K |
MACK Hedge Fund Activity: Q3 2017 in Review
73 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q3 2017, worth a combined $96.8M — up 23% from $78.7M a quarter earlier.
Sellers outnumbered buyers: 55 funds closed out of MACK and 11 opened new positions — a net loss of 44 holders — while 25 trimmed existing stakes and 28 added.
The largest buyer was Newtyn Management, opening a new position worth an estimated $5.21M. The largest seller was Fidelity Investments, cutting an estimated $1.91M.
- 73 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q3 2017, down from 119 in Q2 2017.
- Funds reported $96.8M of Merrimack Pharmaceuticals, Inc. stock for Q3 2017, up 23% quarter-over-quarter.
- 11 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q3 2017 and 55 closed out, a net change of -44 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q3 2017 was Newtyn Management, an estimated $5.21M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q3 2017 was Fidelity Investments, an estimated $1.91M sold.
Based on aggregated 13F filings for Q3 2017.